Document is current
Any future updates will be listed below
-
Authors
Chong, Chia Yuen
Goh, Michelle S.
Porceddu, Sandro V.
Rischin, Danny
Lim, Annette M.
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council (1175929)
- License Information
-
More Information
Article History
Accepted: 9 November 2022
First Online: 13 December 2022
Declarations
:
: No funding has been received for the conduct of this study and/or preparation of this manuscript. CYC is funded by an NHMRC Investigator Grant (#1175929) awarded to DR.
: Sandro V. Porceddu reports serving on advisory boards for Merck Sharp & Dohme and MerckKGgA, and a Steering Committee for Regeneron Pharmaceuticals, Inc. Danny Rischin reports institutional research funding from Regeneron Pharmaceuticals, Inc., Sanofi, Roche, Merck Sharp & Dohme, Bristol-Myers Squibb, GlaxoSmithKline, ALX Oncology and Decibel Therapeutics; and uncompensated scientific committee and advisory board roles for Merck Sharp & Dohme, Regeneron Pharmaceuticals, Inc., Sanofi, and GlaxoSmithKline. Annette M. Lim reports uncompensated consultancy for Eisai, and support from a Peter MacCallum Cancer Centre Discovery Partner Fellowship. Chia Yuen Chong and Michelle S. Goh have no declarations to disclose.
: Not applicable.
: Not applicable.
: Not applicable.
: No datasets were generated and/or analysed during the preparation of this manuscript.
: Not applicable.
: DR and AML conceptualised and planned the manuscript. All authors contributed to the writing and approval of the manuscript.
